STOCK TITAN
  1. Home
  2. Sec-filings
  3. CTXR
  4. [ARS] Citius Pharmaceuticals, Inc. SEC Filing

[ARS] Citius Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
ARS

Rhea-AI Filing Summary

Analyzing...
ARS - Citius Pharmaceuticals, Inc.

ARS Filing - Citius Pharmaceuticals, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: Citius Pharmaceuticals, Inc. (CTXR)

Acceptance Date: 2026-02-24T08:04:14.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Stock CTXR logo
Citius Pharmaceuticals Inc

NASDAQ:CTXR

CTXR Rankings

#6197 Ranked by Market Cap
N/A Ranked by Dividends

CTXR Latest News

Feb 24, 2026
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Feb 13, 2026
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Feb 13, 2026
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Feb 11, 2026
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
Dec 23, 2025
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTXR Latest SEC Filings

Feb 24, 2026
[DEF 14A] Citius Pharmaceuticals, Inc. Definitive Proxy Statement
Feb 17, 2026
[SCHEDULE 13G/A] Citius Pharmaceuticals, Inc. Amended Passive Investment Disclosure
Feb 13, 2026
[8-K] Citius Pharmaceuticals, Inc. Reports Material Event
Feb 13, 2026
[10-Q] Citius Pharmaceuticals, Inc. Quarterly Earnings Report
Jan 28, 2026
[10-K/A] Citius Pharmaceuticals, Inc. Amends Annual Report

CTXR Stock Data

15.89M
21.88M
Biotechnology
Pharmaceutical Preparations
Link
United States
CRANFORD